Moleculin Biotech Reports Positive Annamycin Trial Results

The latest announcement is out from Moleculin Biotech ( (MBRX) ).

On June 4, 2025, Moleculin Biotech reported positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial of Annamycin for treating soft tissue sarcoma lung metastases (STS lung mets). The trial showed a Clinical Benefit Rate of 59.4%, with a median overall survival of 411 days and no cardiotoxicity observed. These results suggest Annamycin as a promising treatment option for STS lung mets, potentially impacting the market expected to grow to $2.6 billion by 2030.

The most recent analyst rating on (MBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and lacks the cardiotoxicity common with currently prescribed anthracyclines.

Average Trading Volume: 443,456

Technical Sentiment Signal: Sell

Current Market Cap: $12.85M

Learn more about MBRX stock on TipRanks’ Stock Analysis page.